14.58 0.00 (0.00%)
After hours: 5:16PM EST
|Bid||12.00 x 1800|
|Ask||15.99 x 1100|
|Day's Range||14.10 - 14.60|
|52 Week Range||10.98 - 29.10|
|Beta (3Y Monthly)||2.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.88|
Flexion Therapeutics, Inc. (FLXN) today announced results from a preclinical study which showed that triamcinolone acetonide (TA) had protective effects on inflamed and/or injured cartilage. Led by Professor Alan Grodzinsky, Sc.D., Director of the Center for Biomedical Engineering at the Massachusetts Institute of Technology (MIT), the study utilized an established in vitro model1 with cartilage explants subjected to inflammatory cytokines and a single impact mechanical injury.
Flexion Therapeutics (FLXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Flexion Therapeutics, Inc. (FLXN) today announced that it will report its fourth-quarter and full-year 2018 financial results after the close of the U.S. financial markets on Thursday, February 28, 2019. The dial-in number for the conference call is 1-855-770-0022 for domestic participants and 1-908-982-4677 for international participants, with Conference ID #2570919. For the past two years, Flexion has been named one of the Best Places to Work by the Boston Business Journal, and a Top Place to Work in Massachusetts by The Boston Globe.
Flexion Therapeutics, Inc. (FLXN) today announced that the results from an open-label Phase 3b clinical trial evaluating the safety and exploratory efficacy of repeat administration of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with osteoarthritis (OA) of the knee were published in Rheumatology and Therapy. The data indicate that repeat administration of ZILRETTA was generally safe and well-tolerated.
Flexion Therapeutics, Inc. (FLXN) announced today that it has been invited to ring the Nasdaq opening bell on Tuesday, February 12, 2019 to commemorate the fifth anniversary of the company’s initial public offering (IPO). Michael Clayman, M.D., President and Chief Executive Officer, will deliver opening remarks at 9:24 a.m. followed by the bell ringing at 9:30 a.m. ET, signifying the start of the day's trading session. “Ringing the Nasdaq opening bell on the fifth anniversary of our IPO serves as a poignant reminder of just how much Flexion has grown and evolved over the past five years,” said Dr. Clayman.
Flexion Therapeutics, Inc. (FLXN) today announced a grant of inducement stock options to 14 new employees for an aggregate of 51,000 shares of common stock. The stock options vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and 1/48 of the shares vesting monthly thereafter, subject to the new employee's continued service relationship with the Company. The stock options are subject to the terms and conditions of the Company's 2013 Equity Incentive Plan and a stock option agreement pursuant to which the stock option was granted.
NEW YORK, Jan. 30, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Flexion Therapeutics, Inc. (FLXN) today announced that Christina Willwerth has been named Chief Strategy Officer. Ms. Willwerth joined Flexion in June 2009, and she most recently served as the company’s Senior Vice President of Program Management and Strategy. In her expanded role, Ms. Willwerth will continue to lead the planning and execution of the company’s strategic vision and priorities, and she has accountability for Flexion’s portfolio development efforts and Human Resources activities.
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks reached 52-week highs Thursday. Down In The Dumps (Biotech Stocks Hitting 52-week lows on Jan. ...
Flexion Therapeutics Inc. shares dove 12% in the extended session Thursday after it released preliminary fourth-quarter revenue and guidance for 2019. The company said it expects fourth-quarter revenue of $9.5 million and full-year revenue of $22.5 million. Wall Street analysts polled by FactSet expected sales of $10.2 million for the quarter and $23.1 million for the year. The company also said it expects $65 million to $80 million of product revenue for 2019, while analysts modeled revenue of $97.8 million. Flexion stock fell 1% during the regular session Thursday, as the S&P 500 index fell 2.5%.
Flexion Therapeutics, Inc. (FLXN) today announced preliminary and unaudited revenue for the fourth-quarter and full-year ended December 31, 2018 and provided initial revenue guidance for 2019. “2018 was a foundational year for ZILRETTA®, and in the first full year of the launch, we saw strong product uptake as we established a broad and growing base of prescribers. Furthermore, the clinical feedback on ZILRETTA from physicians and patients alike continues to be overwhelmingly positive and gratifying,” said Michael Clayman, M.D., President and Chief Executive Officer.
Flexion Therapeutics Inc (NASDAQ: FLXN ) is scheduled to report preliminary fourth-quarter Zilretta sales results and initial 2019 guidance. This will nudge expectations toward reality, as the current ...
Flexion (FLXN) initiates enrollment in phase III study on its pain drug, Zilretta, for the treatment of patients suffering hip osteoarthritis.
Flexion Therapeutics, Inc. (FLXN) today announced that, on December 26, 2018, the first patient was enrolled in a Phase 3 clinical trial to evaluate the safety and efficacy of ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in patients with hip osteoarthritis (OA).
Flexion Therapeutics, Inc. (FLXN) will announce preliminary unaudited revenue for the fourth-quarter and full-year 2018 and provide revenue guidance for 2019 on Thursday, January 3, 2019, after market close. The dial-in number for the conference call is 1-855-770-0022 for domestic participants and 1-908-982-4677 for international participants, with Conference ID #2660538. Flexion Therapeutics (FLXN) is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis.
Flexion Therapeutics, Inc. (FLXN) today announced it submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) to revise the product label for ZILRETTA (triamcinolone acetonide extended-release injectable suspension). The sNDA is based on data from an open-label Phase 3b clinical trial, which indicated that repeat administration of ZILRETTA for treatment of osteoarthritis (OA) knee pain was safe and well tolerated with no deleterious impact on cartilage or joint structure observed through X-ray analysis.
The biotech sector continues to see bearish sentiment and trading action. Small biotech stocks rallied just over 2% on Monday to begin a new trading week, but all those gains were given right back in Tuesday's session.
Anyone researching Flexion Therapeutics Inc (NASDAQ:FLXN) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and there Read More...
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.